CTOs on the Move

NapaJen

www.napajen.com

 
A pioneer in immuno-modulation by cell specific delivery of oligonucleotide drugs to antigen presenting cells completing IND enabling studies for a groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.napajen.com
  • 533 Airport Blvd., #527
    Burlingame, CA USA
  • Phone: 650.685.2429

Executives

Name Title Contact Details

Funding

NapaJen raised $12.4M on 01/09/2019

Similar Companies

Kai Pharmaceuticals

Kai Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gen Trak (Main)

Gen Trak (Main) is a Liberty, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allied BioScience

Allied BioScience is a disruptive biotechnology company specializing in continuously active antimicrobial coatings providing 90 days of surface protection. Working across various industries and commercial settings, its customers include health systems, sports facilities, and other commercial partners. The company is dedicated to saving life through revolutionary science and focuses on developing innovative solutions to create cleaner human environments through long-lasting, always-on antimicrobial coatings.

Bio Clean USA

Bio Clean USA is a Bridgeport, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vericel

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.